Abeona Therapeutics (ABEO)

• Market cap: $280M
• 1 day: -4.1%
• 5 days: 0.82%
• 1 month: -4.47%
• 3 months: -3.73%
• 6 months: -8.4%
• Year to date: -7.53%
• 1 year: 17.46%
• 5 years: -87.33%
• 10 years: -92.48%
• Sector: Healthcare
• Industry: Biotechnology

About: Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Employees: 226